
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Recipient : Boost Neuroscience
Deal Size : Undisclosed
Deal Type : Acquisition
Gate Neurosciences Focuses on Synapse with Boost Neuroscience Acquisition
Details : Acquisition of Boost deepens Gate’s leadership in synapse science and R&D for the development of novel therapeutics that address synaptopathies, or CNS diseases driven by synapse loss and dysfunction.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 19, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Recipient : Boost Neuroscience
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : The University of Pittsburgh School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration
Gate Neurosciences, Pittsburgh Partner for Apimostinel Digital Depression Trial
Details : The collaboration aims the initiation of a Phase 2 to assess the potential for extending the efficacy of GATE-202 (apimostinel), a rapid-acting antidepressant drug.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 03, 2024
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : The University of Pittsburgh School of Medicine
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
Details : Zelquistinel is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2024
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Rebecca Price
Deal Size : Inapplicable
Deal Type : Inapplicable
Apimostinel + Automated Neurocognitive Training for Depression
Details : Apimostinel is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2024
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Rebecca Price
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Beacon Biosignals
Deal Size : Undisclosed
Deal Type : Collaboration
Gate Neurosciences Partners with Beacon Biosignals on EEG Biomarkers for Depression
Details : Beacon's Dreem™ 3S headband will be used to analyze EEG and sleep in depressed patients during Phase 2 trials of zelquistinel, an NMDA receptor modulator.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 24, 2024
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Beacon Biosignals
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GATE-202 (apimostinel) is 2nd generation rapid-acting injectable NMDAR modulator program. Previously demonstrated rapid and robust 24-hour antidepressant effects in a Phase 2a MDD study (p=0.0034)
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers
Details : Apimostinel is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 28, 2022
Lead Product(s) : Apimostinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GATE-101
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GATE-101 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 05, 2020
Lead Product(s) : GATE-101
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AGN-241751 in the Treatment of Major Depressive Disorder
Details : AGN-241751 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 31, 2018
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
AGN-241751 in the Treatment of Major Depressive Disorder
Details : AGN-241751 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2018
Lead Product(s) : Zelquistinel
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
